A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation on B-cell acute lymphoblastic leukemia is limited due to its complex nature and the fact that it affects a relatively small population. The variability in clinical presentation and the lack of identified genetic markers further complicate systematic studies. This condition's aggressive behavior and the need for rapid intervention often overshadow extensive documentation efforts.
To navigate your care effectively, seek a hematologist or oncologist with experience in treating B-cell acute lymphoblastic leukemia. They can provide specialized treatment options tailored to your needs. Additionally, consider exploring clinical trials that may offer access to new therapies. For resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which provides information on rare diseases and potential support avenues.
Inotuzumab ozogamicin is an FDA-approved orphan drug for the treatment of B-cell acute lymphoblastic leukemia. Currently, there are 365 active clinical trials exploring various treatment options and combinations for this condition. You can find more information about these trials at ClinicalTrials.gov by searching for B-cell acute lymphoblastic leukemia.
Actionable guidance for navigating care for B-cell acute lymphoblastic leukemia
To navigate your care effectively, seek a hematologist or oncologist with experience in treating B-cell acute lymphoblastic leukemia. They can provide specialized treatment options tailored to your needs. Additionally, consider exploring clinical trials that may offer access to new therapies. For resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which provides information on rare diseases and potential support avenues.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning B-cell acute lymphoblastic leukemia
Updated Feb 4, 2026
Real-world data confirms that inotuzumab ozogamicin significantly improves remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with a 51.7% overall survival rate. The study highlights a 71.4% MRD-negative status in patients, facilitating further treatment options like ASCT or CAR T.